# PSMD14 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PSMD14 is a JAMM metalloprotease and the intrinsic deubiquitinase of the 19S regulatory particle of the 26S proteasome, essential for cleaving K48-linked polyubiquitin chains to enable substrate degradation and ubiquitin recycling.
- Beyond proteasomal function, PSMD14 deubiquitinates histones (H2AK119ub, H2BK120ub) and stabilizes key transcription factors (ERα, E2F1, CARM1), thereby regulating gene expression, cell cycle progression, and endocrine signaling.
- Overexpression of PSMD14 is a common oncogenic driver in multiple cancers (HCC, melanoma, breast, myeloma, RCC), correlating with poor prognosis, immune evasion (reduced CD8+ T cell infiltration), and resistance to therapies like tamoxifen and bortezomib.
- PSMD14 is implicated in DNA damage repair by deubiquitinating PCNA and FANCD2, promoting homologous recombination, and its inhibition sensitizes cells to DNA-damaging agents and PARP inhibitors.
- Selective PSMD14 inhibitors, such as Capzimin, target the zinc-binding JAMM active site and demonstrate therapeutic potential by killing cancer cells and synergizing with existing chemotherapies.
- Germline heterozygous deletions encompassing PSMD14 at 2q24.2 are associated with neurodevelopmental disorders, suggesting a role for PSMD14 haploinsufficiency in neurological phenotypes.

---

## Executive Summary & Key Metadata

The **PSMD14** gene (Proteasome 26S Subunit, Non-ATPase 14), also known as **POH1** (Pad1 homolog) or **Rpn11** in yeast nomenclature, encodes a 310-amino-acid metalloprotease that functions as the intrinsic deubiquitinase (DUB) of the 19S regulatory particle (RP) of the 26S proteasome. PSMD14 is a JAMM (JAB1/MPN/Mov34) family metalloenzyme that cleaves polyubiquitin chains at the base of the substrate, enabling processive degradation. Beyond its canonical role in proteasomal proteolysis, PSMD14 has emerged as a pleiotropic regulator of transcription, DNA damage repair, chromatin dynamics, and signal transduction, with documented oncogenic functions in hepatocellular carcinoma, melanoma, breast cancer, glioma, multiple myeloma, and clear cell renal cell carcinoma. Its overexpression correlates with poor prognosis, immune evasion, and chemoresistance across multiple malignancies, positioning it as a high-priority therapeutic target.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | PSMD14 |
| UniProt Accession | O00487 |
| Representative PDB ID | 5L4K (human 26S proteasome holoenzyme), 4B0Z (yeast Rpn11) |
| Chromosomal Locus | 2q24.2 |
| Gene Size | ~17.5 kb (genomic DNA) |
| mRNA Length | ~1.5 kb (NM_005805.5) |
| Protein Length | 310 amino acids |
| Molecular Weight | ~34.6 kDa |
| Primary Molecular Function | Deubiquitinase (JAMM/MPN+ metalloprotease); 19S RP subunit; histone H2A/H2B DUB |
| Secondary Functions | Transcription regulation, DNA repair, autophagy, ER-Golgi trafficking, cell cycle control |
| Disease & Pathology Associations | Hepatocellular carcinoma, melanoma, breast cancer, glioma, multiple myeloma, clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, lung adenocarcinoma, ovarian cancer, endometrial cancer, preeclampsia, neurodevelopmental disorders (2q24.2 deletion) |
| Expression Pattern | Ubiquitous; elevated in proliferative tissues and multiple tumor types |
| Subcellular Localization | Nucleus, cytoplasm, chromatin-associated; proteasome-associated |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

PSMD14 is located on the **long arm of chromosome 2** at cytogenetic band **2q24.2**. The gene spans approximately **17.5 kilobases** of genomic DNA on the forward (plus) strand. The precise GRCh38/hg38 coordinates are **chr2:161,298,000–161,315,500** (approximate). The gene is flanked by *TANK* (TRAF family member-associated NF-kB activator) on the telomeric side and *TBR1* (T-box brain transcription factor 1) on the centromeric side. This genomic neighborhood is notable because microdeletions at 2q24.2 encompassing *PSMD14*, *TANK*, and *TBR1* have been associated with neurodevelopmental delay, intellectual disability, and craniofacial dysmorphism. Burrage et al. (2013) narrowed the critical region for these phenotypes to a 0.4 Mb interval that includes *TBR1*, *TANK*, and *PSMD14*, suggesting that haploinsufficiency of PSMD14 may contribute to the neurological phenotype, although the primary driver is likely *TBR1*.

### 1.2 Promoter Architecture and Transcriptional Regulation

The PSMD14 promoter region lacks a canonical TATA box but contains a **CpG island** spanning the transcription start site (TSS), consistent with housekeeping gene characteristics. Multiple **Sp1** (Specificity Protein 1) binding sites are present within the proximal promoter, which are critical for basal transcription. The promoter also contains binding motifs for **NF-Y** (Nuclear Transcription Factor Y), **E2F** family members, and **NRF1** (Nuclear Factor Erythroid 2-Related Factor 1). NRF1 is particularly significant: under conditions of proteasome impairment, NRF1 translocates to the nucleus and upregulates proteasome subunit genes, including PSMD14, in a compensatory feedback loop. This NRF1-mediated regulation is conserved in mammary epithelial cells during metabolic stress, where free fatty acids induce ER stress and NRF1-dependent proteasome gene expression.

### 1.3 Enhancer Elements and Chromatin State

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the PSMD14 locus is marked by **H3K4me1** and **H3K27ac** at several distal enhancer elements located approximately 5 kb upstream and 10 kb downstream of the TSS. These enhancers are bound by **FOXM1**, a master regulator of mitotic progression, in triple-negative breast cancer cells. FOXM1-dependent enhancer activation drives PSMD14 transcription during the G2/M transition, coupling proteasome capacity to cell cycle progression. In addition, the PSMD14 promoter is repressed by **ZEB1** in cholangiocarcinoma cells; cisplatin treatment suppresses ZEB1, leading to derepression of PSMD14 and other proteasome genes—a phenomenon termed the "proteasome bounce-back effect".

### 1.4 Alternative Splicing and Isoforms

The PSMD14 gene produces a single predominant transcript (NM_005805.5) encoding the canonical 310-amino-acid protein. However, several minor splice variants have been catalogued in Ensembl:

- **PSMD14-201** (ENST00000264418.9): Canonical transcript, 1,482 bp coding sequence, 310 aa.
- **PSMD14-202** (ENST00000409355.5): Retains intron 3, predicted to produce a truncated 120-aa protein lacking the JAMM catalytic domain. This isoform is likely subject to nonsense-mediated decay.
- **PSMD14-203** (ENST00000445472.1): Uses an alternative 3' splice acceptor in exon 5, resulting in an in-frame deletion of 12 amino acids within the MPN domain. The functional significance of this isoform is unknown.

Quantitative PCR and RNA-seq data indicate that the canonical isoform constitutes >95% of total PSMD14 mRNA in all tissues examined. No tissue-specific alternative promoters have been identified.

### 1.5 Post-Transcriptional Regulation

PSMD14 mRNA is subject to regulation by **microRNAs**. miR-26b-3p has been shown to directly target the 3' untranslated region (UTR) of PSMD14 in cholangiocarcinoma, reducing its expression and impacting tumor progression. Additionally, the RNA-binding protein **PABPN1** (Poly(A) Binding Protein Nuclear 1) influences alternative polyadenylation site selection in the PSMD14 3' UTR, potentially affecting mRNA stability and translational efficiency. The 3' UTR of PSMD14 is unusually long (~1.2 kb) and contains multiple AU-rich elements (AREs) that may mediate rapid mRNA turnover in response to cellular stress.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The PSMD14 protein (UniProt O00487) is a 310-amino-acid polypeptide with a molecular mass of 34.6 kDa. It belongs to the **MPN (Mpr1-Pad1-N-terminal)** domain family, which is subdivided into MPN+ (catalytic) and MPN− (non-catalytic) subgroups. PSMD14 contains a single MPN+ domain spanning residues **1–260**, followed by a C-terminal extension (residues 261–310) that mediates interactions with other 19S RP subunits.

The domain architecture is as follows:

| **Region** | **Residues** | **Structural/Functional Features** |
|---|---|---|
| N-terminal MPN+ domain | 1–260 | JAMM metalloprotease fold; catalytic site; zinc-binding |
| Catalytic motif (EXnHXHX10D) | 103–133 | Zn²⁺ coordination; nucleophilic water activation |
| Active site glutamate | Glu104 | General base for catalysis |
| Histidine residues | His112, His114 | Zn²⁺ coordination |
| Aspartate | Asp133 | Zn²⁺ coordination |
| C-terminal helix | 261–310 | Interaction with Rpn8/PSMD8 and Rpn11 dimerization |

### 2.2 The JAMM Metalloprotease Fold

The MPN+ domain of PSMD14 adopts a **βαββαβ** sandwich fold characteristic of the JAMM family. The catalytic site is located in a shallow groove on the surface of the domain, formed by the conserved **EXnHXHX10D** motif. This motif coordinates a single **zinc ion** in a tetrahedral geometry: the side chains of His112 and His114, the carboxylate of Asp133, and a water molecule complete the coordination sphere. The catalytic mechanism involves:

1. **Substrate recognition**: The ubiquitin C-terminus (Gly76) inserts into the active site groove.
2. **Zinc polarization**: The Zn²⁺ ion polarizes the isopeptide carbonyl oxygen, increasing its electrophilicity.
3. **Nucleophilic attack**: The zinc-bound water molecule is deprotonated by Glu104, generating a hydroxide ion.
4. **Tetrahedral intermediate**: The hydroxide attacks the isopeptide carbonyl carbon, forming a tetrahedral oxyanion intermediate stabilized by the zinc ion.
5. **Collapse and product release**: The intermediate collapses, cleaving the isopeptide bond between ubiquitin Gly76 and the substrate lysine ε-amino group.

This mechanism is distinct from that of cysteine protease DUBs (e.g., USP, UCH families) and is insensitive to classical DUB inhibitors such as ubiquitin aldehyde, but sensitive to zinc chelators and specific small-molecule inhibitors like **capzimin** and **O-phenanthroline**.

### 2.3 Structural Context within the 26S Proteasome

Within the 26S proteasome, PSMD14 forms a heterodimer with **PSMD8 (Rpn8)**, another MPN family protein that lacks catalytic activity (MPN−). The PSMD14–PSMD8 heterodimer is a component of the **lid subcomplex** of the 19S RP. The C-terminal regions of both proteins form a coiled-coil interaction, while their MPN domains pack against each other. This heterodimerization is essential for the stability of both proteins; in the absence of PSMD8, PSMD14 is rapidly degraded.

Cryo-electron microscopy (cryo-EM) structures of the human 26S proteasome (PDB: 5L4K, 6MSB) reveal that the PSMD14–PSMD8 dimer is positioned at the **top of the lid**, directly above the central pore of the ATPase ring (Rpt1–Rpt6). This positioning is critical for PSMD14's function: as the ATPase ring unfolds and translocates the substrate into the 20S core particle, the polyubiquitin chain is pulled toward the PSMD14 active site, where it is cleaved en bloc. This "**shuttle mechanism**" ensures that ubiquitin is recycled while the substrate is degraded.

### 2.4 Conformational Dynamics and Allosteric Regulation

PSMD14 exists in at least two conformational states within the proteasome: an **open (active)** state and a **closed (inactive)** state. In the closed state, the active site is occluded by an insertion loop (residues 110–125) that must be displaced for substrate access. The transition between states is regulated by:

- **ATP hydrolysis** in the Rpt ring, which induces conformational changes transmitted through the lid.
- **Ubiquitin chain length**: K48-linked chains of at least four ubiquitins are required for efficient PSMD14 activation.
- **Post-translational modification**: Phosphorylation of Ser14 by CK2 (Casein Kinase 2) enhances PSMD14 activity, while phosphorylation of Thr120 by ATM (Ataxia Telangiectasia Mutated) inhibits it.

### 2.5 Non-Proteasomal Structural Pools

A significant fraction of cellular PSMD14 exists in a **free, non-proteasome-associated form**. This pool is structurally distinct: free PSMD14 forms a homodimer (rather than heterodimer with PSMD8) and exhibits altered substrate specificity. Free PSMD14 can deubiquitinate **histone H2A** (at Lys119) and **H2B** (at Lys120), as well as non-histone substrates such as **ERα**, **CARM1**, and **SMAD3**. The structural basis for this promiscuity is not fully resolved but likely involves the exposure of a broader substrate-binding surface in the homodimeric state.

### 2.6 Interactive 3D Visualization

> **🔬 Interactive 3D Protein Visualizer: Load PSMD14 (PDB: true)**
>
> [**Launch the interactive 3D protein viewer for PSMD14 (UniProt O00487)**](/tools/protein-structure-viewer?source=alphafold&accession=O00487)
>
> This tool loads the experimentally determined structure of the human 26S proteasome (PDB: 5L4K) and highlights the PSMD14 subunit in context. Users can:
> - Toggle between cartoon, surface, and sphere representations.
> - Highlight the catalytic zinc ion (shown as a grey sphere) and the EXnHXHX10D motif.
> - Measure distances between catalytic residues and the ubiquitin C-terminus.
> - Superimpose the free PSMD14 homodimer model (AlphaFold) onto the proteasome-bound heterodimer.
> - Animate the open-to-closed conformational transition using morph coordinates.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Function: Proteasomal Deubiquitination

The primary and best-characterized function of PSMD14 is its role as the **deubiquitinase of the 19S regulatory particle**. During proteasomal degradation, substrates tagged with K48-linked polyubiquitin chains are recognized by the 19S RP. PSMD14 removes the entire ubiquitin chain from the substrate in a single cleavage event at the base of the chain, a process known as **en bloc deubiquitination**. This activity is essential for:

- **Substrate translocation**: The unfolded substrate must be free of ubiquitin to pass through the narrow pore of the 20S core particle.
- **Ubiquitin recycling**: Free ubiquitin is released for reuse in new conjugation reactions.
- **Proteasome processivity**: PSMD14 activity is coupled to ATP hydrolysis by the Rpt ring; inhibition of PSMD14 stalls substrate degradation.

The importance of PSMD14 in global proteostasis is underscored by studies in fission yeast (*Schizosaccharomyces pombe*), where the ortholog *pad1+* is essential for viability. Conditional knockdown of PSMD14 in human cells leads to the accumulation of polyubiquitinated proteins, ER stress, and apoptosis.

### 3.2 Non-Canonical Functions: Chromatin and Transcription Regulation

Beyond its proteasomal role, PSMD14 has emerged as a key regulator of **gene expression** through its ability to deubiquitinate histone proteins and transcription factors.

#### 3.2.1 Histone H2A/H2B Deubiquitination

PSMD14 removes monoubiquitin from **histone H2A at Lys119** (H2AK119ub) and **histone H2B at Lys120** (H2BK120ub). These marks have opposing effects on transcription:

- **H2AK119ub** is associated with transcriptional repression (Polycomb-mediated silencing). PSMD14-mediated removal of H2AK119ub reactivates silenced genes.
- **H2BK120ub** is associated with transcriptional elongation. PSMD14-mediated removal of H2BK120ub can either activate or repress transcription depending on the genomic context.

In multiple myeloma, PSMD14 interacts with the **MLL (Mixed Lineage Leukemia)** complex and deubiquitinates H2AK119 at HOX gene loci, maintaining their expression and driving myelomagenesis. In melanoma, PSMD14-mediated H2A deubiquitination promotes the expression of genes involved in cell survival and MAPK inhibitor resistance.

#### 3.2.2 Transcription Factor Stabilization

PSMD14 directly deubiquitinates and stabilizes several transcription factors:

- **ERα (Estrogen Receptor α)**: PSMD14 deubiquitinates ERα at Lys302, protecting it from proteasomal degradation. This stabilizes ERα protein levels and enhances estrogen signaling in luminal breast cancer. PSMD14 overexpression confers tamoxifen resistance, while PSMD14 knockdown restores tamoxifen sensitivity.
- **SMAD3**: PSMD14 deubiquitinates SMAD3, a key effector of TGF-β signaling. In melanoma, PSMD14-mediated SMAD3 stabilization inhibits cell growth, suggesting a tumor-suppressive role in this context.
- **E2F1**: PSMD14 stabilizes E2F1, a master regulator of cell cycle progression. In glioma, the ECT2/PSMD14/PTTG1 axis promotes proliferation by stabilizing E2F1.
- **CARM1 (Coactivator-Associated Arginine Methyltransferase 1)**: PSMD14 deubiquitinates CARM1, enhancing its stability and promoting the transcriptional activation of FERMT1, which drives hepatocellular carcinoma proliferation and metastasis.
- **IRF3 (Interferon Regulatory Factor 3)**: PSMD14 deubiquitinates IRF3, balancing type I interferon production and immune suppression.

#### 3.2.3 Signaling Kinase Receptors

PSMD14 also regulates receptor signaling by deubiquitinating receptor kinases:

- **ALK2 (Activin A Receptor Type 2A)**: PSMD14 deubiquitinates ALK2, stabilizing it and enhancing BMP6 signaling. This promotes tumor growth and chemoresistance in multiple cancer types.
- **JAK/STAT3 Pathway**: In clear cell renal cell carcinoma, PSMD14 activates JAK/STAT3 signaling, driving tumor progression.

### 3.3 Regulation of Autophagy and Membrane Trafficking

PSMD14 plays a critical role in **macroautophagy** by regulating Golgi-to-ER retrograde transport. High-content siRNA screening identified PSMD14 as a key regulator of Amyloid Precursor Protein (APP) trafficking. Mechanistically, PSMD14 deubiquitinates components of the **COG (Conserved Oligomeric Golgi)** complex and the **GARP (Golgi-Associated Retrograde Protein)** complex, which are required for retrograde vesicle fusion. Loss of PSMD14 disrupts Golgi morphology, impairs autophagosome formation, and leads to the accumulation of autophagic substrates.

### 3.4 DNA Damage Response

PSMD14 is recruited to sites of DNA double-strand breaks (DSBs) where it deubiquitinates **PCNA** (Proliferating Cell Nuclear Antigen) and **FANCD2** (Fanconi Anemia Complementation Group D2). This activity promotes homologous recombination repair and maintains genome stability. PSMD14 depletion sensitizes cells to ionizing radiation and PARP inhibitors, suggesting a potential synthetic lethal interaction.

### 3.5 Protein-Protein Interaction Network

PSMD14 participates in a dense protein-protein interaction network. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and BioGRID include:

| **Interactor** | **Function** | **Consequence of Interaction** |
|---|---|---|
| PSMD8 (Rpn8) | 19S lid subunit | Heterodimer formation; proteasome assembly |
| PSMD11 (Rpn6) | 19S lid subunit | Lid stability; proteasome assembly |
| PSMD3 (Rpn3), PSMD6 (Rpn7), PSMD7 (Rpn8), PSMD12 (Rpn5), PSMD13 (Rpn9) | 19S lid subunits | Lid subcomplex integrity |
| PSMC1-6 (Rpt1-6) | 19S ATPase ring | Coupling of deubiquitination to translocation |
| HAPSTR1 | Heat shock protein-associated | Ovarian cancer progression |
| LRPPRC | Leucine-rich PPR motif-containing protein | Ovarian cancer progression |
| ECT2 | Epithelial cell transforming sequence 2 | Glioma proliferation |
| PTTG1 | Pituitary tumor-transforming gene 1 | Glioma proliferation |
| SP1 | Specificity Protein 1 | Melanoma metabolism |
| GYS1 | Glycogen synthase 1 | Melanoma metabolism |
| ERα | Estrogen receptor α | Breast cancer progression |
| CARM1 | Arginine methyltransferase | HCC proliferation/metastasis |
| ALK2 | BMP receptor | Tumor growth/chemoresistance |
| SMAD3 | TGF-β effector | Melanoma growth inhibition |
| IRF3 | Interferon regulatory factor 3 | Antiviral immunity |
| XPO1 | Exportin 1 | Co-expression rewiring in cancer |

### 3.6 Signaling Pathway Diagram

The following Mermaid diagram summarizes the major signaling pathways involving PSMD14:

```mermaid
flowchart TD
    subgraph "Ubiquitin-Proteasome System"
        UBI["("Ubiquitin")"] -->|"K48 polyubiquitination"| SUB["("Substrate")"]
        SUB -->|"Recognition"| 19S["("19S Regulatory Particle")"]
        19S -->|"ATP hydrolysis"| UNFOLD["("Substrate Unfolding")"]
        UNFOLD -->|"Translocation"| 20S["("20S Core Particle")"]
        20S -->|"Degradation"| PEPTIDES["("Peptides")"]
        19S --> PSMD14["("PSMD14")"]
        PSMD14 -->|"En bloc cleavage"| UBI
    end

    subgraph "Non-Canonical Functions"
        PSMD14 -->|"Deubiquitinates H2AK119ub"| CHROM["("Chromatin Remodeling")"]
        PSMD14 -->|"Deubiquitinates H2BK120ub"| TRANS["("Transcriptional Elongation")"]
        PSMD14 -->|"Stabilizes ERα"| ER["("Estrogen Signaling")"]
        PSMD14 -->|"Stabilizes CARM1"| CARM1["("CARM1/FERMT1 Axis")"]
        PSMD14 -->|"Stabilizes E2F1"| E2F1["("Cell Cycle Progression")"]
        PSMD14 -->|"Stabilizes ALK2"| BMP["("BMP6 Signaling")"]
        PSMD14 -->|"Stabilizes SMAD3"| TGFB["("TGF-β Signaling")"]
        PSMD14 -->|"Stabilizes IRF3"| IFN["("Type I Interferon")"]
        PSMD14 -->|"Regulates COG/GARP"| GOLGI["("Golgi-ER Retrograde Transport")"]
        GOLGI --> AUTOPH["("Macroautophagy")"]
    end

    subgraph "Pathological Consequences"
        CHROM -->|"HCC, Myeloma"| CANCER1["("Tumor Progression")"]
        ER -->|"Breast Cancer"| CANCER2["("Endocrine Resistance")"]
        CARM1 -->|"HCC"| CANCER3["("Metastasis")"]
        E2F1 -->|"Glioma"| CANCER4["("Proliferation")"]
        BMP -->|"Multiple Cancers"| CANCER5["("Chemoresistance")"]
        TGFB -->|"Melanoma"| SUPPRESS["("Tumor Suppression")"]
        IFN -->|"Immune Evasion"| IMMUNE["("Immune Microenvironment")"]
        AUTOPH -->|"Proteostasis"| HOMEOSTASIS["("Cellular Homeostasis")"]
    end
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Chromosomal Aberrations

#### 4.1.1 2q24.2 Microdeletions

PSMD14 is located within the **2q24.2 microdeletion syndrome** critical region. Patients with heterozygous deletions encompassing PSMD14, TANK, and TBR1 present with:

- **Intellectual disability** (moderate to severe)
- **Developmental delay**
- **Craniofacial dysmorphism** (microcephaly, prominent forehead, hypertelorism)
- **Seizures** (in some cases)
- **Short stature**
- **Behavioral abnormalities** (autism spectrum features)

Belengeanu et al. (2014) reported a 20-month-old girl with a de novo 2.3 Mb deletion at 2q24.2q24.3 presenting with developmental delay and dysmorphic features. Burrage et al. (2013) further narrowed the critical region to 0.4 Mb, identifying TBR1, TANK, and PSMD14 as candidate genes. While TBR1 haploinsufficiency is the primary driver of the neurodevelopmental phenotype, PSMD14 haploinsufficiency may contribute through impaired proteostasis and altered Wnt/β-catenin signaling during cortical development.

#### 4.1.2 Point Mutations

To date, no disease-causing germline point mutations in PSMD14 have been reported in the literature. The gene appears to be under strong purifying selection, consistent with its essential role in proteostasis. However, the Genome Aggregation Database (gnomAD) lists several rare missense variants with minor allele frequencies <0.01%, including:

- **p.Arg8Trp** (rs148048896): Located in the N-terminal region; predicted to be benign.
- **p.Val45Ile** (rs141693108): Located in the MPN domain; predicted to be tolerated.
- **p.Glu104Lys**: This variant would disrupt the catalytic glutamate and is predicted to be deleterious, but has not been observed in population databases.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in PSMD14 are rare across cancer types, with an overall frequency of <1% in TCGA datasets. However, copy number gains and mRNA overexpression are common. The following somatic alterations have been catalogued:

| **Cancer Type** | **Alteration** | **Frequency** | **Clinical Significance** |
|---|---|---|---|
| Hepatocellular carcinoma | mRNA overexpression | ~60% | Poor overall survival; recurrence after resection |
| Melanoma | mRNA overexpression; copy number gain | ~40% | MAPK inhibitor resistance |
| Breast cancer (luminal) | mRNA overexpression | ~50% | Tamoxifen resistance |
| Multiple myeloma | mRNA overexpression | ~70% | Bortezomib resistance |
| Clear cell renal cell carcinoma | mRNA overexpression | ~55% | JAK/STAT3 activation; poor prognosis |
| Glioma | mRNA overexpression | ~45% | E2F1 stabilization; proliferation |
| Pancreatic ductal adenocarcinoma | mRNA overexpression | ~50% | Poor prognosis |
| Lung adenocarcinoma | mRNA overexpression | ~45% | Immune infiltration; poor prognosis |
| Ovarian cancer | mRNA overexpression | ~50% | Chemoresistance; metastasis |
| Endometrial cancer | mRNA overexpression | ~55% | Poor prognosis |

### 4.3 Functional Consequences of PSMD14 Overexpression

PSMD14 overexpression drives tumorigenesis through multiple mechanisms:

1. **Enhanced proteasomal flux**: Increased PSMD14 activity accelerates the degradation of tumor suppressors (e.g., p53, p27) and pro-apoptotic proteins.
2. **Histone deubiquitination**: PSMD14-mediated removal of H2AK119ub reactivates oncogenic transcriptional programs.
3. **Transcription factor stabilization**: PSMD14 stabilizes oncogenic transcription factors (ERα, E2F1, CARM1) while promoting the degradation of tumor suppressors.
4. **Immune evasion**: PSMD14 overexpression correlates with reduced CD8+ T cell infiltration and increased regulatory T cell (Treg) infiltration in HCC and LUAD.
5. **Metabolic reprogramming**: In melanoma, PSMD14 forms an axis with SP1 and GYS1 to promote glycogen metabolism and therapy resistance.

### 4.4 PSMD14 in Non-Cancer Pathologies

#### 4.4.1 Preeclampsia

PSMD14 expression is significantly reduced in placental tissues from patients with preeclampsia. The transcription factor **HEY1** (Hes-Related Family BHLH Transcription Factor with YRPW Motif 1) directly activates PSMD14 transcription in trophoblast cells. HEY1-PSMD14 signaling regulates trophoblast invasion, migration, and endometrial angiogenesis. Reduced PSMD14 expression impairs these processes, contributing to the shallow placental implantation characteristic of preeclampsia.

#### 4.4.2 Neurodegenerative Disorders

PSMD14 expression is altered in Alzheimer's disease (AD) brain tissues, particularly in the hippocampus and entorhinal cortex. Reduced PSMD14 expression may impair proteasomal clearance of amyloid-β and tau aggregates, contributing to neurodegeneration. Conversely, PSMD14 upregulation in the retrosplenial cortex is associated with contextual fear memory formation, suggesting a role in synaptic plasticity.

#### 4.4.3 Intervertebral Disc Degeneration

Tandem mass tag-based proteomic analysis of degenerated human intervertebral discs identified PSMD14 as one of the differentially expressed proteins, with reduced expression in Pfirrmann Grade IV discs compared to Grade II. This suggests that impaired proteostasis contributes to disc degeneration.

#### 4.4.4 Thyroid-Associated Ophthalmopathy

Machine learning analysis identified PSMD14 as part of a hypoxia-immune gene hub associated with thyroid-associated ophthalmopathy (TAO). PSMD14 expression in orbital fibroblasts may contribute to the inflammatory and hypoxic microenvironment characteristic of TAO.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of PSMD14

Several viruses have evolved mechanisms to exploit PSMD14 activity for their replication:

#### 5.1.1 Human Papillomavirus (HPV)

The HPV E6 oncoprotein, in complex with E6AP (UBE3A), targets p53 for proteasomal degradation. PSMD14 is required for the efficient degradation of p53 in HPV-positive cells, as PSMD14-mediated deubiquitination of the E6/E6AP/p53 complex is necessary for processive degradation. PSMD14 knockdown in HPV-positive cervical cancer cells restores p53 expression and induces apoptosis.

#### 5.1.2 Herpes Simplex Virus Type 1 (HSV-1)

Oncolytic HSV-1 (oHSV) infection alters the expression of proteasome subunits, including PSMD14, in infected tumor cells. The virus hijacks the host proteasome to degrade antiviral signaling molecules, and PSMD14 activity is required for efficient viral replication. Transcriptome analysis of oHSV-infected cells reveals that PSMD14 is among the most significantly upregulated proteasome genes, suggesting that the virus actively induces PSMD14 expression to enhance its replication.

#### 5.1.3 Hepatitis B Virus (HBV)

HBV infection is a major risk factor for hepatocellular carcinoma. PSMD14 expression is elevated in HBV-associated HCC tissues, and this elevation correlates with immune evasion and poor prognosis. The HBV X protein (HBx) has been shown to upregulate PSMD14 transcription through the NF-κB pathway, creating a feed-forward loop that promotes viral replication and hepatocarcinogenesis.

### 5.2 Bacterial Effectors

#### 5.2.1 *Candidatus Liberibacter asiaticus*

The citrus pathogen *Candidatus Liberibacter asiaticus* (Las) secretes the effector protein **SDE1** (Sec-Delivered Effector 1), which induces chlorosis in *Nicotiana benthamiana* by suppressing the host RNA helicase NbDDX3. While the direct interaction between SDE1 and PSMD14 has not been demonstrated, transcriptomic analysis of SDE1-expressing plants reveals downregulation of proteasome subunit genes, including PSMD14 orthologs, suggesting that the effector may modulate host proteostasis to enhance virulence.

### 5.3 Immune Evasion Mechanisms

PSMD14 plays a dual role in immune regulation:

1. **Antigen Presentation**: PSMD14 is required for the generation of MHC class I-presented peptides. Its inhibition reduces antigen presentation, impairing CD8+ T cell recognition of tumor cells.
2. **Immune Checkpoint Regulation**: PSMD14 deubiquitinates and stabilizes **PD-L1** (Programmed Death-Ligand 1) in some cancer types, promoting immune evasion. Conversely, PSMD14-mediated stabilization of IRF3 enhances type I interferon production, promoting antiviral immunity.

In HCC and LUAD, high PSMD14 expression correlates with:
- Reduced CD8+ T cell infiltration
- Increased Treg infiltration
- Elevated expression of immune checkpoint molecules (PD-1, CTLA-4, LAG-3)
- Resistance to immune checkpoint inhibitor therapy

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PSMD14 as a Therapeutic Target

PSMD14 has emerged as a high-value therapeutic target for several reasons:

1. **Druggable active site**: The JAMM metalloprotease active site is structurally distinct from cysteine protease DUBs, allowing for selective inhibition.
2. **Oncogenic driver**: PSMD14 overexpression drives tumor progression and therapy resistance across multiple cancer types.
3. **Dual mechanism**: PSMD14 inhibition simultaneously impairs proteasomal degradation and disrupts non-canonical oncogenic signaling.
4. **Sensitization to existing therapies**: PSMD14 inhibition sensitizes cancer cells to proteasome inhibitors (bortezomib, carfilzomib), MAPK inhibitors (vemurafenib), and endocrine therapies (tamoxifen).

### 6.2 Small-Molecule Inhibitors

#### 6.2.1 Capzimin

**Capzimin** (6-((2-cyclohexyl-2-hydroxy-2-phenylacetamido)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid) is the first selective PSMD14 inhibitor developed. It binds to the JAMM active site, coordinating the catalytic zinc ion and blocking substrate access. Capzimin:

- Inhibits PSMD14 with an IC₅₀ of ~40 nM in biochemical assays.
- Selectively kills multiple myeloma cells, including bortezomib-resistant lines.
- Synergizes with bortezomib and carfilzomib in vitro and in vivo.
- Reduces tumor growth in xenograft models of melanoma and HCC.

#### 6.2.2 O-Phenanthroline

**1,10-Phenanthroline** is a zinc chelator that inhibits PSMD14 with an IC₅₀ of ~10 μM. While not selective for PSMD14 (it inhibits all metalloproteases), it has been used extensively as a tool compound to validate PSMD14 as a therapeutic target. O-phenanthroline treatment recapitulates the effects of PSMD14 knockdown, including accumulation of polyubiquitinated proteins and apoptosis.

#### 6.2.3 Thiolutin

**Thiolutin**, a natural product isolated from *Streptomyces* species, inhibits PSMD14 by covalently modifying the catalytic cysteine in the MPN domain (despite PSMD14 being a metalloprotease, thiolutin shows some cross-reactivity). It exhibits anti-proliferative activity against multiple myeloma and melanoma cell lines.

#### 6.2.4 3-(4-Hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (Compound 9g)

This investigational compound was identified through structure-based virtual screening. It binds to the PSMD14 active site with a Kd of ~200 nM and inhibits PSMD14 activity in cellular assays. Compound 9g suppresses the growth of clear cell renal cell carcinoma cells and enhances the efficacy of sunitinib.

### Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)